Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.81 |
| ▸ | BRAF | P15056 | 7/20 | 0.81 |
| ▸ | RIPK3 | Q9Y572 | 6/20 | 0.81 |
| ▸ | KDR | P35968 | 2/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.81 |
| ▸ | IKBKB | O14920 | 1/20 | 0.81 |
| ▸ | RAF1 | P04049 | 1/20 | 0.81 |
| ▸ | PDGFA | P04085 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.81 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.81 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.81 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.81 |
| ▸ | CDK2 | P24941 | 1/20 | 0.81 |
| ▸ | GSK3B | P49841 | 1/20 | 0.81 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.81 |
| ▸ | TEK | Q02763 | 1/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823554 | 0.94 | RIPK1 (0.78) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL22275546 | 0.92 | RIPK1 (0.82) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL28496454 | 0.91 | RIPK1 (0.81) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL823682 | 0.89 | BRAF (1.00) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL25412537 | 0.87 | RIPK1 (1.00) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL30358255 | 0.87 | RIPK1 (1.00) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL2453182 | 0.85 | RIPK1 (0.80) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL29025431 | 0.84 | RIPK1 (0.94) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL29025422 | 0.84 | RIPK1 (0.93) | RIPK1BRAFRIPK3KDRCHEK1 | |
| SCHEMBL22567120 | 0.84 | BRAF (0.90) | RIPK1BRAFRIPK3KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112094248-A | Substituted benzothiazole compound and application thereof | 中国人民解放军海军军医大学 | 2020-12-18 | — | — | CN | disclosed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | RIPK1 736/4885BRAF 1/4885RIPK3 700/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | RIPK1 736/4885BRAF 1/4885RIPK3 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.